Statistical controversies in clinical research: futility analyses in oncology - lessons on potential pitfalls from a randomised controlled trial.
Authors
Lesaffre, EEdelman, M
Hanna, N
Park, K
Thatcher, Nick
Willemsen, S
Gaschler-Markefski, B
Kaiser, R
Manegold, C
Affiliation
L-Biostat, KU Leuven, Leuven, Belgium, and Erasmus Medical Center, Rotterdam, The NetherlandsIssue Date
2017-02-09
Metadata
Show full item recordCitation
Statistical controversies in clinical research: futility analyses in oncology - lessons on potential pitfalls from a randomised controlled trial. 2017, Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdx042PubMed ID
28184431Type
ArticleLanguage
enISSN
1569-8041ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdx042
Scopus Count
Collections
Related articles
- Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.
- Authors: Hanna NH, Kaiser R, Sullivan RN, Aren OR, Ahn MJ, Tiangco B, Voccia I, Pawel JV, Kovcin V, Agulnik J, Gaschler-Markefski B, Barrueco J, Sikken P, Schloss C, Kim JH, LUME-Lung 2 Study group
- Issue date: 2016 Dec
- Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
- Authors: Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, von Pawel J, Gottfried M, Bondarenko I, Liao M, Gann CN, Barrueco J, Gaschler-Markefski B, Novello S, LUME-Lung 1 Study Group
- Issue date: 2014 Feb
- Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
- Authors: Smith CL, Jin Y, Raddad E, McNearney TA, Ni X, Monteith D, Brown R, Deeg MA, Schnitzer T
- Issue date: 2019 Jan
- Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.
- Authors: Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, Wang Z, Shu Y, Shi J, Hu Y, Wang Q, Cheng Y, Wu F, Chen J, Lin X, Wang Y, Huang J, Cui J, Cao L, Liu Y, Zhang Y, Pan Y, Zhao J, Wang L, Chang J, Chen Q, Ren X, Zhang W, Fan Y, He Z, Fang J, Gu K, Dong X, Zhang T, Shi W, Zou J, CameL Study Group
- Issue date: 2021 Mar
- A systematic survey of randomised trials that stopped early for reasons of futility.
- Authors: Walter SD, Han H, Guyatt GH, Bassler D, Bhatnagar N, Gloy V, Schandelmaier S, Briel M
- Issue date: 2020 Jan 16